JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 3862
CAS [1446090-77-2]
MF C25H17F3N4O3MW 478.42
BGB-283 is an orally available dual RAF kinase/EGFR inhibitor. It potently inhibits BRAF family proteins (wild-type ARAF, BRAF, CRAF and BRAF V600E), BRAF(V600E)-activated ERK phosphorylation and cell proliferation, and demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. Further, it uniquely displays inhibitory activity towards both BRAF monomeric and dimeric forms, and is considered to be the next generation inhibitor to potentially address resistances associated with increased BRAF dimer formation in response to treatment with first-generation BRAF inhibitors.
KEYWORDS: BGB-283 | Supplier | RAF kinase and EGFR inhibitor | Lifirafenib | BGB283 | BGB 283 | CT-BGB283 | CAS [1446090-77-2] | MEK | RAF | Inhibitor | Enzymes
rel-5-[[(1S,1aS,6bR)-1a,6b-dihydro-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1H-cyclopropa[b]benzofuran-5-yl]oxy]-3,4-dihydro1,8-Naphthyridin-2(1H)-one
[1446090-77-2]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields